

TARGETING apoptosis

Monday, 19 December 2022

Starhotel Excelsior, BOLOGNA

Organizing Secretariat



Free Registration

www.proeventi.it

President: G. Martinelli

Chairs: G. Marconi, G. Martinelli, C. Papayannidis

Co-Chairs: C. Cerchione, A. Curti, A. Lucchesi,
G. Musuraca, G. Simonetti

09.00 Participant Registration

09.30 Welcome and Introduction
G. Martinelli

SESSION I

Deciphering apoptosis

Chairs: C. Papayannidis, E. Petracchi

09.50 Targeting apoptosis pathways in
mutated leukemia
G. Simonetti

10.10 Targeting pyroptosis, necroptosis and
ferroptosis pathways, in cancer, leukemia and
inflammatory diseases
D. Girelli

10.30 The mitochondrial machinery
D. Cilloni

10.50 New emerging relationship between apoptosis
and immunity
M. Colombo

11.10 – 11.30 Coffee Break

11.30 A live cell imaging pipeline for quantifying
mitochondrial inter-organelle interaction.
(Venetoclax/S384)
A. Hamacher-Brady

11.50 How to improve BCL2 inhibition
V. Gaidano

12.10 Autophagy and apoptosis: lesson from RAS
mutation
M. Konopleva

12.30 New evidence in "forcing" apoptosis
V. Ciminale

12.50 Panel Discussion

13.30 Lunch

SESSION II

New therapeutic approaches to induce apoptosis SIGNALING: Present and Future

Chairs: M. Gottardi, R. Lemoli, C. Papayannidis

14.30 Special lecture: Deciphering apoptosis
M. Andreeff

14.50 BCL2 inhibitors: Venetoclax as a model
D. Cilloni

15.10 BCL2 inhibitors: Venetoclax and Decitabine or
Azacytadine alone and in combination with IDH inhibitors
as a eradication leukemia model
C. DiNardo

15.30 BCL2 inhibitors in other disease:
The Venetoclax history in MM
C. Cerchione

15.50 The BCL2/BCLx inhibitor Navitoclax in clinical
(T-ALL) experience
E. Jabbour

16.10P.M. Is the Triplet combination
(Gilteritinib, Magrolimab and CD123)
a potential strategy for eradication of AML?
N. Daver

16.30 Optimizing the use of BCL2 inhibitors:
the Avalon experience
G. Marconi

16.50 BCL2 related alterations and response to therapy in
lymphoid neoplasms: IRST experience.
A. Ferrari

17.10 Panel Discussion

18.00 Closing Remarks
G. Martinelli

with the unrestricted educational grant of
abbvie werfen